Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • May 29, 2026

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 28, 2026

Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year?

Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Zacks Investment Research • May 26, 2026

Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • May 21, 2026

Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026.

PRNewsWire • May 19, 2026

Is This the Right Time to Hold DGX Stock in Your Portfolio?

Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.

Zacks Investment Research • May 19, 2026

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.

Barrons • May 14, 2026

Quest Diagnostics: Updating Levels After Q1 Earnings

Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA.

Seeking Alpha • May 7, 2026

Bullish Quarterly Results: 3 Companies Raising Guidance

Guidance upgrades are generally among the most bullish announcements a company can make, signaling that the outlook is even better than previously expected.

Zacks Investment Research • May 7, 2026

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • May 6, 2026